Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACER53: Viltolarsen in Duchenne Muscular Dystrophy
NCT04060199Phase 3Completed
- Sponsor
- NS Pharma, Inc.
- Start
- Apr 2020
- Primary completion
- Oct 2023
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 19
01
Overview
A Phase 3 trial of viltolarsen in Duchenne muscular dystrophy (DMD), sponsored by NS Pharma, Inc.. Started Apr 2020; status: completed.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT04060199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04060199.